Citizens JMP raised the firm’s price target on DBV Technologies (DBVT) to $21 from $15 and keeps an Outperform rating on the shares. Xolair’s food allergy launch has more than 50K patients on drug within the first year despite some key hindrances, which may be limiting its use in Viaskin Peanut’s target 1-7 year old population, the analyst tells investors in a research note. The firm sees the Phase 3 VITESSE data in 4-7 year olds in Q4 as the next key catalyst for shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DBVT:
- Buy Rating for DBV Technologies Driven by Promising Viaskin Peanut Potential and Strong Market Opportunity
- DBV Technologies files to sell 289.01M ordinary shares for holders
- DBV Technologies price target raised to $16 from $7 at H.C. Wainwright
- DBV Technologies price target raised to $15 from $10 at Citizens JMP
- DBVT Upcoming Earnings Report: What to Expect?